NASDAQ:OPHT IVERIC bio Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.80 +0.14 (+2.47 %) (As of 11/20/2020 12:00 AM ET) Add Compare Share Today's Range$5.52Now: $5.80▼$5.8350-Day Range$1.13MA: $1.30▼$1.3952-Week Range$1.02Now: $5.80▼$4.50Volume615,399 shsAverage Volume159,109 shsMarket Capitalization$240.24 millionP/E RatioN/ADividend YieldN/ABeta1.49 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for IVERIC bio. Previous Next 2.7 Community Rank Outperform VotesIVERIC bio has received 372 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIVERIC bio has received 312 “underperform” votes. (Add your “underperform” vote.)Community SentimentIVERIC bio has received 54.39% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IVERIC bio and other stocks. Vote “Outperform” if you believe OPHT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIVERIC bio does not currently pay a dividend.Dividend GrowthIVERIC bio does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IVERIC bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of IVERIC bio is held by insiders.Percentage Held by Institutions45.39% of the stock of IVERIC bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IVERIC bio are expected to decrease in the coming year, from ($1.21) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IVERIC bio is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IVERIC bio is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIVERIC bio has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.71 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPHT Previous Symbol CUSIPN/A CIK1410939 Webwww.ophthotech.com Phone(212) 845-8200Employees35 Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$209.98 million Price / Sales1.14 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book1.93Profitability EPS (Most Recent Fiscal Year)($1.67) Net Income$63.09 million Net MarginsN/A Return on Equity-141.53% Return on Assets-41.88%Miscellaneous Outstanding Shares41,420,000Market Cap$240.24 million Next Earnings DateN/A OptionableOptionable Receive OPHT News and Ratings via Email Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter. IVERIC bio (NASDAQ:OPHT) Frequently Asked Questions What stocks does MarketBeat like better than IVERIC bio? Wall Street analysts have given IVERIC bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IVERIC bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:OPHT) posted its quarterly earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.02. View IVERIC bio's earnings history. Who are some of IVERIC bio's key competitors? Some companies that are related to IVERIC bio include Rhythm Pharmaceuticals (RYTM), Syndax Pharmaceuticals (SNDX), Arvinas (ARVN), Vectura Group (VEGPF), Morphic (MORF), Frequency Therapeutics (FREQ), Enanta Pharmaceuticals (ENTA), Amphastar Pharmaceuticals (AMPH), Protagonist Therapeutics (PTGX), Calliditas Therapeutics AB (publ) (CALT), Provention Bio (PRVB), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), Cara Therapeutics (CARA) and Zafgen (ZFGN). View all competitors. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), (CELG) and Bausch Health Companies (BHC). Who are IVERIC bio's key executives? IVERIC bio's management team includes the following people: Glenn P. Sblendorio, President, Chief Executive Officer & DirectorKeith Westby, Chief Operating Officer & Senior Vice PresidentDavid F. Carroll, Chief Financial Officer, Treasurer & SVPKourous A. Rezaei, Chief Medical Officer & Senior Vice PresidentAbraham Scaria, Chief Scientific Officer What is IVERIC bio's stock symbol? IVERIC bio trades on the NASDAQ under the ticker symbol "OPHT." What is IVERIC bio's stock price today? One share of OPHT stock can currently be purchased for approximately $5.80. How big of a company is IVERIC bio? IVERIC bio has a market capitalization of $240.24 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $63.09 million in net income (profit) each year or ($1.67) on an earnings per share basis. IVERIC bio employs 35 workers across the globe. What is IVERIC bio's official website? The official website for IVERIC bio is www.ophthotech.com. How can I contact IVERIC bio? IVERIC bio's mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at (212) 845-8200 or via email at [email protected] This page was last updated on 11/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
